December 1, 2022 in Kineta Press Release

Kineta to Present KVA12123 VISTA Blocking Immunotherapy Program at Antibody Engineering and Therapeutics Conference

Seattle, WA — (December 1, 2022) Kineta, Inc. (“Kineta” or the “Company”), a clinical-stage biotechnology company focused on developing next-generation immunotherapies to address cancer immune resista ...

Read More
November 15, 2022 in Kineta Press Release

Kineta Announces FDA Acceptance of Investigational New Drug (IND) Application for KVA12123 for the Treatment of Advanced Solid Tumors

Seattle, WA – (November 15, 2022) Kineta, Inc. (“Kineta” or the “Company”), a clinical-stage biotechnology company focused on developing next-generation immunotherapies that address cancer immune resi ...

Read More
Post placeholder image
November 10, 2022 in Kineta Press Release

Kineta Announces Effectiveness of Registration Statement on Form S-4 in Connection with Proposed Reverse Merger with Yumanity Therapeutics (YMTX)

Special Meeting of stockholders to approve asset sale and merger to be held on December 13, 2022 BOSTON, Nov. 10, 2022 -- Yumanity Therapeutics, Inc. ("Yumanity" or the "Company") (Nasdaq: YMTX) ...

Read More
October 17, 2022 in Kineta Press Release

Kineta Announces Clinical Collaboration with Merck to Evaluate KVA12123 in Combination with KEYTRUDA® (pembrolizumab) in Cancer Patients with Advanced Solid Tumors

Kineta’s VISTA blocking immunotherapy KVA12123 (formerly referred to as KVA12.1) to be evaluated in patients with advanced solid tumors Clinical trial anticipated to begin in late 2022 Seattle, ...

Read More
October 12, 2022 in Kineta Press Release

Kineta to Present Anti-CD27 Agonist Preclinical Program at AACR Conference on Tumor Immunology and Immunotherapy

Seattle, WA – (October 12, 2022) Kineta, Inc. (“Kineta” or the “Company”), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology, announced today that ...

Read More